AlloVir, Inc. (NASDAQ:ALVR – Get Free Report)’s share price was up 3.5% on Thursday . The stock traded as high as $4.33 and last traded at $4.17. Approximately 79,551 shares were traded during mid-day trading, an increase of 407% from the average daily volume of 15,685 shares. The stock had previously closed at $4.03.
AlloVir Stock Up 3.5%
The business’s fifty day moving average is $4.23 and its 200 day moving average is $6.00. The firm has a market capitalization of $21.03 million, a price-to-earnings ratio of -0.21 and a beta of 0.63.
AlloVir Company Profile
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
Further Reading
- Five stocks we like better than AlloVir
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
